Forefront Energy Source Welcoming Amanda M. Laird, MD, FACS require fuel for growth and ob- Tumors Rutgers Cancer stein College of Medicine where she joined the faculty there as an Assistant Professor in the Department of Surgery in 2012 and served as Director of endocrine Surgery. Dr. Laird treats endocrine tumors of the thyroid, parathyroid glands, and adrenal glands. These tumors are uniquely different as they may secrete hormones in excess and may occur as a part of a familial genetic syndrome. She also treats neuroendocrine tumors which have similar characteristics and may occur anywhere throughout the body. Working closely with a multidisciplinary team that includes surgical oncologists, endocrinologists, medical oncologists, nuclear medicine radiologists, radiation oncologists, nurses, and genetic counselors, Dr. Laird provides coordinated care for patients and tracks their tain this nutrition from the body of the patient in which they reside. This fuel comes in the form of proteins, amino acids, lipids, sugars and other metabolites, which are used to synthesize the building blocks for new cancer cells and to help maintain normal cellular functions. The demand for fuel is most likely higher in cancer cells than most normal tissues, which has led researchers to question: What specific fuels are important for cancer cells? Where do they come from? What are they used for? Can the dependency of tumors on nutrients supplied from the host be therapeutically exploited? Institute of New Jersey is pleased to announce the arrival of Amanda M. Laird, MD, FACS (right) as Chief of the new Section of endocrine Surgery in the Division of Surgical Oncology at Rutgers Robert Wood Johnson Medical School, where she is also an Associate Professor in the Department of Surgery. In collaboration with Rutgers Cancer Institute Director Steven K. Libutti, MD, FACS and Stanley Trooskin, MD, FACS, chief of general surgery at Rutgers Robert Wood Johnson Medical School, she is leading the creation and operation of a new Endocrine and Neuroendocrine Tumor Program at Rutgers Cancer Institute. Dr. Laird most recently was at Montefiore Medical Center and Albert ein- A New Program The The laboratories of Eileen White, PhD (above, right), deputy director, chief scientific officer, and associate director for basic science at Rutgers Cancer Institute of New Jersey and distinguished professor of molecular biology and biochemistry in the School of Arts and Sciences at Rutgers University; and Joshua D. Rabinowitz, MD, PhD (above, left), professor in the Department of Chemistry and Lewis-Sigler Institute for Integrative Genomics at Princeton University, aim to answer these questions with the support of a $2.24 million competing renewal of a grant (R01 CA163591) awarded from the National Cancer Institute. The research will focus on melanomas and lung cancers caused by mutations in genes known as K-ras and Braf. I Endocrine and Neuroendocrine Tumor Program at Rutgers Cancer Institute of New Jersey offers a multidisciplinary, comprehensive approach for the full spectrum of treatment for these unique tumors including medullary thyroid cancer, parathyroid tumors, adrenal tumors and hormone-producing adrenal tumors, adrenocortical cancer and others. Our team of endocrine surgeons, neurosurgeons, surgical oncologists, endocrinologists, medical oncologists, radiation oncologists, radiologists, nurses, social workers, and genetic counselors collaborate to ensure that each patient is cared for with an individualized approach, providing the most advanced treatment options available. Our clinicians also work closely with our scientists on basic, clinical and translational research activities in an effort to advance our understanding of these unique tumors and provide patients with access to the latest clinical trials and novel therapies. Since some endocrine and neuroendocrine tumors may occur together within genetic syndromes, we also offer both genetic counseling and a full spectrum of testing, as well as social services support as part of our patient-centered approach. I 4 I Cancer Connection I Summer 2017